OBJECTIVES
This Peers & Perspectives program, moderated by Alicia Morgans, MD, MPH, with panelist Paul Sieber, MD, explores how personalized immunotherapy and real-world data are transforming management strategies for advanced prostate cancer. Through an in-depth, conversational format, the experts review the evolution of the mCRPC treatment landscape, analyze long-term safety and survival outcomes with sipuleucel-T and AR-targeted therapies, and discuss how genomic testing, patient selection, and multidisciplinary coordination influence care. The discussion emphasizes the integration of real-world evidence with clinical judgment to advance individualized, mechanism-based treatment pathways that improve patient quality of life and outcomes.
In this program, expert faculty discuss the evolving approach to prostate cancer detection, focusing on novel biomarkers that go beyond traditional PSA testing. The conversation highlights emerging clinical evidence, practical integration into diagnostic workflows, and strategies to enhance patient selection, reduce unnecessary biopsies, and support shared decision-making in urologic care.
Bryan Mehlhaff, MD and Kelly L. Stratton, MD, FACS discuss how oral androgen deprivation therapy (ADT) options like relugolix offer distinct advantages over traditional injectable therapies in prostate cancer treatment, including rapid onset and recovery, reduced cardiovascular risk, improved patient convenience, and elimination of testosterone flare, while exploring their integration into modern treatment paradigms that increasingly emphasize combination therapies and shared decision-making.
Mark Tyson II, MD, MPH, and Gary D. Steinberg, MD, discuss how NMIBC management has evolved significantly with new FDA approvals including pembrolizumab, nogapendekin alfa, and nadofaragene for BCG-unresponsive disease. Novel therapies in development include sustained-release platforms and immunotherapies.
A panel of urologic and oncologic experts provide comprehensive insights on optimal utilization of androgen deprivation therapy in patients with prostate cancer, highlighting the evolving treatment landscape and recent clinical trial data.
Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, discuss key conversation points surrounding high-risk BCG-unresponsive NMIBC as presented at ASCO 2024 in Chicago, Illinois.
Neal Shore, MD, FACS, and Brian M. Shuch, MD, have a comprehensive discussion on the evolving imaging and diagnostic landscape in kidney cancer, highlighting emerging PET imaging agents.
Matthew Smith, MD, PhD, and Brian T. Helfand, MD, have a comprehensive discussion on the treatment of patients with prostate cancer, highlighting the treatment of nonmetastatic CRPC and metastatic HSPC and the role of AR pathway inhibitors.
Christopher M. Pieczonka, MD and Jose De La Cerda, MD, MPH engage in a comprehensive discussion on the nuances of abiraterone formulations for treating metastatic castration-resistant prostate cancer (mCRPC). They explore patient assessment, treatment considerations for special populations, and clinical practice management tailored to the diverse needs of patients with mCRPC.
Michelle Semins, MD, and Seth Bechis, MD, explore recent advancements in treating urinary stones, focusing on the significance of intrarenal pressure (IRP), its effect on patient outcomes, and methods to decrease elevated IRP.
Experts David Morris, MD, FACS, and Benjamin Garmezy, MD, share a dynamic discussion on the respective roles of combination therapy and multidisciplinary care in the current treatment landscape of advanced prostate cancer.
Key opinion leaders discuss the latest PSMA-PET imaging updates for prostate cancer and consider how real-world practice has evolved.
This Uroview features discussion between Dr. Alexandra Rogers and Dr. Scott MacDiarmid about current and emerging treatments for overactive bladder, with a focus on implantable tibial nerve stimulation devices in this space.
Steven Finkelstein, MD, DABR, FACRO, and Louis J. Mazzarelli, MD, react to the article, “A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT,” by Pernthaler B, et al.
Two experts in urology provide a discussion on currently available screening and risk assessment tools in prostate cancer and emphasize the importance of early detection.
Analysis of Gallium-68 PSMA 9 (prostate-specific membrane antigen) targeted PET (positron emission tomography) imaging and its impact on staging and prostate cancer.
Specialists in urology discuss the significance of germline testing in prostate cancer.
